Non-peptide MDM2 Inhibitors for p53 Reactivation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer therapies face challenges due to cancer cells' resistance to apoptosis, largely attributed to the inhibitory actions of MDM2 on p53, leading to defects in apoptosis pathways and cell cycle regulation, which limits the effectiveness of existing treatments.
Innovation Solution
Development of non-peptide small molecule inhibitors that target the interaction between p53 and MDM2, thereby inhibiting the negative regulation of p53 by MDM2, increasing p53's activity to induce apoptosis and cell cycle arrest in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If peptide-based inhibitors are used to block p53-MDM2 interaction, then high-affinity binding is achieved, but cell permeability and in vivo bioavailability deteriorate
Solution Approach 1:
The patent changes the chemical parameters of the inhibitor by transitioning from peptide-based to non-peptide small molecule structures. This fundamental parameter change allows the molecule to maintain high binding affinity to the p53-MDM2 interface while achieving adequate cell permeability and oral bioavailability, resolving the contradiction between binding reliability and ease of cellular delivery
Solution Approach 2:
The patent employs small molecule inhibitors that can be administered systemically and distributed throughout the body, replacing the need for complex peptide delivery systems. These small molecules achieve their therapeutic effect transiently but can be repeatedly administered, providing a practical solution that balances binding affinity with pharmacokinetic properties
2Productivity
If high doses of anticancer agents are administered to overcome apoptosis resistance, then cancer cell killing effectiveness is improved, but toxic side effects on normal cells increase
Solution Approach 1:
The patent introduces small molecule inhibitors as intermediaries that specifically block the MDM2-p53 interaction. This intermediary action restores p53-mediated apoptosis in cancer cells without requiring high doses of cytotoxic chemotherapy agents, thereby achieving effective cancer cell killing while reducing toxic side effects on normal cells
Solution Approach 2:
The patent extracts and targets the specific molecular mechanism (MDM2-p53 interaction) that confers apoptosis resistance to cancer cells. By isolating and inhibiting this specific interaction rather than using broad-spectrum cytotoxic agents, the treatment achieves selective cancer cell killing with reduced off-target toxicity
Data Source
AI summary
The invention relates to small molecules which function as inhibitors of the interaction between p53 and MDM2. The invention also relates to the use of these compounds for inhibiting cell growth, inducing cell death, inducing cell cycle arrest and/or sensitizing cells to additional agent(s).